Clinical Outcomes of Extremity Synovial Sarcoma

Year 2022, , 222 - 226, 30.06.2022

Halil Sezgin Semis , Aliekber Yapar , Fener Çelebi Güray Toğral , Bedii Safak Gungor

https://doi.org/10.18663/tjcl.1034445

Abstract

Aim: The aim of this study is to emphasize the demographic data, follow-up results and the importance of approach to
these tumors of synovial sarcoma, which is a rare tumor in the extremities.
Material and Methods: In this study, twenty patients who were operated on for extremity synovial sarcoma between
2008 and 2018 at Dr. Abdurrahman Yurtaslan Oncology Hospital were retrospectively analyzed. Demographic information,
surgical treatments, follow-up periods, recurrence and metastases of the patients were recorded.
Results: Twenty patients with a diagnosis of synovial sarcoma with a mean age of 32.7 (range, 13 to 66) years were included
in this study. According to the localization, it was observed that the tumors were mostly located in the thigh (25%), cruris
(25%) and ankle (25%). It was observed that the tumor size was 5 cm or more in 70% of the patients. While 55% (n=11) of
the patients had metastases at the time of diagnosis (lung), recurrence developed in 25% of the patients during follow-up.
Wide resection was performed as the primary surgical treatment in 85% of the patients, while 75% received RT, only 30%
received CT. 25% of patients died during follow-up. The mean survival time of the patients was 109.4±8.9 months. While
the 3-year survival rate was 90%, the 5-year survival rate decreased to 80%. There was no significant difference in survival
times according to gender, age, side, grade, tumor size, metastasis, RT, KT and recurrence status.
Conclusion: In conclusion, synovial sarcoma is a rare malignant soft tissue sarcoma with high grade and high metastasis capacity.
For understanding the characteristics of synovial sarcoma, multicenter studies with a larger number of patients are needed

Keywords

Synovial Sarcoma, Outcome, Extremity

Ekstremite yerleşimli sinovial sarkomun klinik sonuçları

Abstract

Amaç: Bu çalışmanın amacı ekstremitelerde nadir görülen bir tümör olan sinoviyal sarkomun demografik verilerini, takip
sonuçlarını ve bu tümörlere yaklaşımın önemini vurgulamaktır.
Gereç ve Yöntemler: Bu çalışmada Dr. Abdurrahman Yurtaslan Onkoloji Hastanesi'nde 2008-2018 yılları arasında
ekstremite sinoviyal sarkomu nedeniyle ameliyat edilen 20 hasta retrospektif olarak incelendi. Hastaların demografik
bilgileri, cerrahi tedavileri, takip süreleri, nüks ve metastazları kaydedildi.
Bulgular: Ortalama yaşı 32.7 (dağılım, 13-66) yıl olan sinoviyal sarkom tanısı alan 20 hasta bu çalışmaya dahil edildi.
Lokalizasyona göre tümörlerin en çok uyluk (%25), kruris (%25) ve ayak bileği (%25) yerleşimli olduğu görüldü. Hastaların
%70'inde tümör boyutunun 5 cm ve üzerinde olduğu görüldü. Hastaların %55'inde (n=11) tanı anında (akciğer) metastaz
varken, %25'inde takip sırasında nüks gelişti. Hastaların %85'inde primer cerrahi tedavi olarak geniş rezeksiyon yapılırken,
%75'ine RT, sadece %30'una BT uygulandı. Hastaların %25'i takip sırasında öldü. Hastaların ortalama sağkalım süresi
109.4±8.9 ay idi. 3 yıllık sağkalım oranı %90 iken, 5 yıllık sağ kalım oranı %80'e düşmüştür. Cinsiyet, yaş, taraf, derece, tümör
boyutu, metastaz, RT, KT ve nüks durumuna göre sağkalım süreleri arasında anlamlı fark yoktu.
Sonuç: Sonuç olarak, sinoviyal sarkom, yüksek dereceli ve yüksek metastaz kapasiteli, nadir görülen bir malign yumuşak doku
sarkomudur. Sinoviyal sarkomun özelliklerini anlamak için daha fazla hasta sayısı ile çok merkezli çalışmalara ihtiyaç vardır

Keywords

sinovial sarkom, sonuç, Ekstremite

References

• 1. Kasper B, Gil T, D′Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 2007; 62: 9–15.
• 2. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma. Identification of low and high risk groups. Cancer 1999; 15; 85: 2596-607.
• 3. Trassard M, Le Doussal V, Hacène K, et al. Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J Clin Oncol 2001; 15; 19: 525-34.
• 4. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115: 3537–47.
• 5. Ulucakoy C, Yapar A, Öztürk R, Toğral G, Güngör BŞ. Is There Any Prognostic Relationship Between Malignant Peripheral Nerve Sheath Tumors And NF Type 1?. Acta Oncologica Turcica 2020; 53: 46-56.
• 6. Yapar A, Atalay IB, Ulucakoy C, Ozturk R, Karakoc Y. The relationship between recurrence and lung metastasis in giant cell tumor of bone. Turkish Journal of Clinics and Laboratory 2020; 11: 23-8.
• 7. Al-Hussaini H, Hogg D, Blackstein ME et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011; 231789.
• 8. Lewis JJ, Antonescu CR, Leung DH et al. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18: 2087-94.
• 9. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. Journal of Clinical Oncology 2004; 22: 4040–50.
• 10. Mackenzie, D. H. Synovial sarcoma. A review of 58 cases. Cancer 1996; 19: 169-80.
• 11. Zhang H, Huang W, Feng Q et al. Clinical Significance and Risk Factors of Local Recurrence in Synovial Sarcoma: A Retrospective Analysis of 171 Cases. Front Surg. 2022; 8: 736146.